Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keppra And Velcade Rivals Among Sawai’s New Listings

Japanese Firm Unveils Raft Of Five New Products In Nine Presentations

Executive Summary

Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.

You may also be interested in...



What’s Next? Five Things To Look Out For In September

As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.

ANDA Sponsors Swarm On Vimpat Blockbuster As Protection Expires

UCB’s Vimpat blockbuster has finally fallen to generic competition in the US, after its intellectual property was skewered by ANDA sponsors as part of a failed challenge before the US Supreme Court in 2018 and 2019.

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel